News
Phase 1 data for Spyre Therapeutics, Inc.'s SPY002 & SPY072 show promise in autoimmune treatments. Advancing to Phase 2 trials. Click for my updated look at SYRE.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback